AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Study Overview: AstraZeneca is currently conducting a clinical study titled ‘Ondexxya for Intravenous Injection 200mg Drug Use Result Investigation (All Case Investigation).’ The primary aim is to assess the safety and effectiveness of Ondexxya, focusing on detecting unknown adverse reactions and understanding factors affecting its safety and efficacy.
Intervention/Treatment: The study investigates Ondexxya, an intravenous injection used to reverse anticoagulation effects in patients. It aims to ensure the drug’s safety and effectiveness in real-world settings.
Study Design: This is an observational cohort study with a prospective time perspective. It focuses on collecting data on the safety and effectiveness of Ondexxya under actual use conditions without any intervention model or masking.
Study Timeline: The study began on June 2, 2022, with the last update submitted on July 8, 2025. These dates are crucial as they indicate the study’s progress and ongoing data collection efforts.
Market Implications: The ongoing study of Ondexxya could influence AstraZeneca’s stock performance by potentially enhancing investor confidence if the results demonstrate safety and effectiveness. This could also impact competitors in the anticoagulation reversal market, highlighting AstraZeneca’s commitment to drug safety.
The study is currently recruiting, with further details available on the ClinicalTrials portal.